WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and W ...

WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, Latinos and ...

Core Article Summary - Tevogen Bio Holdings Inc expands its AI-focused collaboration with Microsoft to enhance its PredicTcell technology, leveraging Microsoft's AI, cloud capabilities, and health/life sciences expertise to accelerate target identification and pre-clinical processes [1] - The collaboration aims to strengthen Tevogen Bio's pipeline of innovative immunotherapies for infectious diseases and cancers [1] TevogenAI and Microsoft Integration - TevogenAI integrates Microsoft's advanced AI tools and Azure cloud platform to achieve two key objectives: 1) Rapidly expand the ExacTcell™ Technology Pre-Clinical Pipeline by using machine learning for critical simulations to accelerate new target identification [2] 2) Develop proprietary algorithms to decode HLA-T cell interactions, enhancing understanding of immune responses and opening new therapeutic avenues [3] Strategic Goals and Leadership Perspective - The expanded relationship with Microsoft is seen as a milestone in revolutionizing immunotherapy, with a focus on delivering precise and personalized treatments at an accelerated pace [4] - Tevogen Bio is proactively investigating potential treatments for HPV using its proprietary ExacTcell™ technology, aiming to deliver an HPV-specific CTL treatment [4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified precision T cell therapies for infectious diseases, cancers, and neurological disorders [5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and nine pending US patents [5] - Tevogen Bio is led by a team of experienced industry leaders and scientists, emphasizing accessible personalized therapeutics and disruptive business models to sustain medical innovation [6] Additional Notes - The collaboration with Microsoft is part of the previously announced Microsoft for Startups program [7] - PredicTcell, Tevogen Bio's proprietary technology, is designed for predictive, precision T cell target identification [7]

The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discover ...

WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transf ...

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio. In October 2023, Tevogen Bio launched its ar ...

Full name for licenses is Anthony Joseph ("A.J.") Cataldo II, PhD, CPA. Retired university accounting professor, CMA, CGMA and author of 10 books and 200+ articles and columns in 50+ different journals and outlets, with experience as CFO, Government Auditor, Public Accountant and Litigation Support Expert Witness in cases involving GM, Ford, and other big cap firms. Years ago, the Securities and Exchange Commission used 3 of my research articles in a fraud case. I have taught at 10 universities including No ...

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, "Pioneering the Economics of Health: Balancing Access and Outcomes," during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together global thoug ...

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pioneering the Economics of Health: Balancing Access and Outcomes,” during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together global thou ...

WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities for key leaders to further expand company capabilities. As part of this leadership evolution: Tapan V Shah, Head of Investor Relations and Corporate Development, will take on added responsibil ...